ITGR

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 27, 2002, for Wilson Greatbatch Technologies, Inc. (Note: The input metadata referenced "Integer Holdings Corp," but the filing text explicitly identifies the registrant as Wilson Greatbatch Technologies, Inc.). The Company operates in two segments: Medical Technology (batteries, capacitors, and components for implantable devices) and Commercial Power Sources (batteries for aerospace and oil/gas). A significant event during the period was the acquisition of Globe Tool and Manufacturing Company, Inc. ("Greatbatch-Globe") on July 9, 2002, for approximately $48 million in cash and $9 million in assumed debt.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 18% ($7.0 million) for the quarter and 19% ($19.1 million) for the nine months compared to the prior year. Medical Technology revenues drove this growth, particularly in ICD batteries (+40% QoQ) and components (+44% QoQ), aided by the Greatbatch-Globe acquisition.
• Margin Compression: Gross margin declined to 42% from 43% in the prior quarter and from 45% in the prior nine-month period. This was attributed to a $0.6 million purchase accounting charge related to the Greatbatch-Globe acquisition and production yield issues at Greatbatch-Sierra.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose 34% for the quarter and 33% for the nine months, primarily due to the inclusion of acquired entities and infrastructure development costs.
• Non-Recurring Charges: The Company recorded a $1.72 million write-off of a noncompete agreement and a $1.55 million write-off of an investment in an unrelated company. These charges reduced net income for the period.
• Liquidity: Cash and cash equivalents dropped significantly from $43.3 million to $3.3 million, primarily due to the $32.0 million cash outlay for the Greatbatch-Globe acquisition.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects capital expenditures to increase in 2002 to support expanded production capacity and R&D facilities.
• Debt Structure: The Company amended its credit facility to $120 million ($100 million term loan, $20 million revolver) to finance the acquisition. The facility matures in July 2007 and carries variable interest rates (Prime + 0.25% or LIBOR + 2.375%). The Company is currently in compliance with all financial covenants.
• Accounting Changes: The Company adopted SFAS No. 142, which ceased the amortization of goodwill and indefinite-lived intangibles, significantly reducing amortization expenses compared to the prior year.
• Risks: Key risks include dependence on a limited number of customers, product obsolescence, pricing pressure, and the successful integration of recent acquisitions. The Company also faces market risk regarding interest rate fluctuations on its variable-rate debt.

Investor Verification Checklist

• Acquisition Integration: Verify the operational integration and revenue contribution of Greatbatch-Globe and Greatbatch-Sierra to ensure projected synergies are realized.
• Liquidity Position: Monitor the low cash balance ($3.3 million) relative to the $85.8 million term loan and upcoming capital expenditure plans.
• Debt Covenants: Confirm continued compliance with EBITDA and leverage ratios required by the amended credit facility.
• Non-Recurring Items: Assess the impact of the $3.27 million in total non-recurring write-offs (noncompete and investment) on the true operating performance.
• Customer Concentration: Review the extent of reliance on major medical device manufacturers for revenue stability.